NASDAQ · Analyst Forecast

Coeptis Therapeutics Holdings, Inc. (COEP) Analyst Forecast

$10.99 NASDAQ: COEP Market Cap $38.62M

Revenue and earnings estimates published by analysts covering Coeptis Therapeutics Holdings, Inc. (COEP), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Coeptis Therapeutics Holdings, Inc., analysts forecast revenue falling from $3.50T in 2023 to $766.7B in 2027; the average estimate for 2027 earnings per share is $-3.60; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.

Revenue forecast (USD millions)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

Year	Low	Average	High	Analysts
2023	$3.50T	$3.50T	$3.50T	1
2025	$1.36T	$1.36T	$1.36T	1
2026	$1.02T	$1.02T	$1.02T	1
2027	$766.7B	$766.7B	$766.7B	1

Earnings per share forecast

Year	Low	Average	High	Analysts
2023	$-17.00	$-17.00	$-17.00	1
2025	$-3.40	$-3.40	$-3.40	1
2026	$-3.40	$-3.40	$-3.40	1
2027	$-3.60	$-3.60	$-3.60	1

Coeptis Therapeutics Holdings, Inc. (COEP) forecast — frequently asked questions

What are analysts forecasting for Coeptis Therapeutics Holdings, Inc.'s earnings?

The average analyst estimate for Coeptis Therapeutics Holdings, Inc. (COEP) earnings per share in 2027 is -3.60, with individual estimates between -3.60 and -3.60.

How much revenue is Coeptis Therapeutics Holdings, Inc. expected to make?

Analysts forecast Coeptis Therapeutics Holdings, Inc. (COEP) revenue of $766.7B in 2027, based on 1 published estimates.

How many analysts cover COEP?

1 analyst contribute estimates for Coeptis Therapeutics Holdings, Inc. (COEP). Thin coverage makes an average less reliable.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.